Company Overview of TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd., a pharmaceutical company, engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes. It offers Nemonoxacina, a drug-resistant anti-infection drug for community acquired pneumonia, diabetic foot infection, skin infections, and nosocomial pneumonia; and stem cell mobilizer products to mobilize stem cells and progenitor cells from the bone marrow into peripheral circulation, as well as for chemosensitization treatment of leukemia patients. The company also provides hepatitis C virus protease inhibitors, anti-influenza drugs, anti-gram negative drugs, and bacteria drugs. TaiGen Biotechnology Co., Ltd. was founded in 2001 and is...
138 Shin Ming Road
Founded in 2001
Key Executives for TaiGen Biotechnology Co., Ltd.
Founder, Executive Chairman, Chief Executive Officer, President and Member of Steering Committee
Senior Vice President of Research
Senior Vice President of Product Development and Marketing General Manager of Taigen Beijing
Vice President of Business Development
Compensation as of Fiscal Year 2015.
TaiGen Biotechnology Co., Ltd. Key Developments
TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial in Acute Myeloid Leukemia in China
Apr 30 15
TaiGen Biotechnology Co., Ltd. announced the initiation of first burixafor trial in China. The study titled "A Phase I/II Study of Burixafor Plus Fludarabine and CytarabineÂ in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)" is an open-label study to determine the safety and efficacy of burixafor in combination with two chemotherapeutic agents, fludarabine and cytaribine and will enroll up to 15 patients.Â In addition to maximum tolerated dose of burixafor, other efficacy endpoints such as complete response, disease free survival, and overall survival will also be evaluated. The study will be led by Prof. Wang JianXiang, a hematologist/oncologist at the Institute of Hematology and Blood Diseases Hospital in Tianjin under a clinical trial authorization for Class 1.1 new drug from China FDA.
TaiGen Biotechnology Co., Ltd. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 04:15 PM
Apr 13 15
TaiGen Biotechnology Co., Ltd. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 04:15 PM. Venue: Kerry Hotel, Pudong, Shanghai, China.
TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany
Mar 18 15
TaiGen Biotechnology Company, Limited announced the signing of an agreement to collaborate with Cellex GmbH and the University Hospital Carl Gustav Carus Dresden in Germany in an investigator-initiated clinical trial using burixafor in stem cell mobilization in healthy donors. The study titled "Burixafor in allogeneic poor mobilizers" is a Phase 2 open-label study to determine the effect of a single dose of burixafor in up to 37 poor mobilizers. The rate of donation success will be measured as the primary endpoint. Under the terms of the agreement, Cellex will be responsible for obtaining clinical trial approval and conduct of the trial and assume all associated costs. TaiGen will have the option to obtain and use the data for future development and filing of market authorization.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|